PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Vertex, CRISPR Therapeutics’ sickle cell gene therapy wins PRIME designation

Vertex Pharmaceuticals and CRISPR Therapeutics have been awarded a Priority Medicines (PRIME) designation from the European Medicines Agency for their CRISPR/Cas9 gene therapy, designed to treat severe sickle cell disease (SCD).

The gene therapy, CTX001, is currently being evaluated as a treatment for patients suffering with transfusion-dependent beta thalassemia (TDT) or severe (SCD).

Based on the companies’ progress in this clinical programme so far, CTX001 has been granted a Regenerative Medicine Advanced Therapy (RMAT), Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA), as well as an Orphan Drug Designation from the European Commission, for TDT and SCD.

CTX001 is being jointly developed by Vertex and CRISPR under a co-development and co-commercialisation agreement, initially signed back in 2015. The TDT/SCD gene therapy is the first treatment to emerge from the joint research programme.

Under the PRIME designation, the development plans and evaluation of CTX001 will be expedited to help get the treatment to patients who need it faster. The designation was granted based on data from the ongoing phase I/II trial of CTX001 in patients with SCD.

The gene therapy works by collecting patients own hematopoietic stem and progenitor cells from the blood, which are then edited using CRISPR/Cas9 technology. The edited cells – CTX001 – are then infused back into the patient’s system as part of a stem cell transplant.

CRISPR Therapeutics has established strategic collaborations with a number of other high-profile pharma companies, including Bayer and ViaCyte.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026